We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

83 hedge funds and large institutions have $235M invested in OncoMed Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 44 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 14

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

6% more funds holding

Funds holding: 7883 (+5)

7% more call options, than puts

Call options by funds: $1.51M | Put options by funds: $1.41M

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

8% less capital invested

Capital invested by funds: $257M → $235M (-$21.5M)

Holders
83
Holders Change
+5
Holders Change %
+6.41%
% of All Funds
2.24%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
13
Increased
44
Reduced
14
Closed
8
Calls
$1.51M
Puts
$1.41M
Net Calls
+$97K
Net Calls Change
-$103K
Name Holding Trade Value Shares
Change
Change in
Stake
ASP
1
Adams Street Partners
Illinois
$37.4M
SAM
2
Sectoral Asset Management
Quebec, Canada
$30.8M -$4.05M -164,044 -11%
BI
3
BVF Inc
California
$28.5M -$478K -19,400 -2%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$19.3M +$116K +4,700 +0.6%
BFA
5
BlackRock Fund Advisors
California
$18.6M +$2.47M +100,028 +14%
Vanguard Group
6
Vanguard Group
Pennsylvania
$8.74M +$633K +25,659 +7%
AC
7
Apex Capital
California
$8.73M +$1.56M +63,100 +19%
Franklin Resources
8
Franklin Resources
California
$5.61M
State Street
9
State Street
Massachusetts
$4.92M +$809K +32,793 +17%
Primecap Management
10
Primecap Management
California
$4.29M -$382K -15,493 -8%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$4.22M +$691K +28,034 +18%
CC
12
Cannell & Co
New York
$4.12M +$3.36M +136,349 +292%
Norges Bank
13
Norges Bank
Norway
$4.1M
Northern Trust
14
Northern Trust
Illinois
$3.34M +$353K +14,297 +11%
ICM
15
IronBridge Capital Management
Illinois
$3.31M +$182K +7,400 +5%
BIT
16
BlackRock Institutional Trust
California
$3.1M +$235K +9,527 +7%
Bank of America
17
Bank of America
North Carolina
$2.79M +$736K +29,856 +32%
JP Morgan Chase
18
JP Morgan Chase
New York
$2.53M +$716K +29,036 +35%
CS
19
Credit Suisse
Switzerland
$2.48M +$706K +28,617 +35%
Morgan Stanley
20
Morgan Stanley
New York
$2.34M +$31.1K +1,262 +1%
IHM
21
Iguana Healthcare Management
New York
$2.25M +$2.47M +100,000 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$2.12M +$568K +23,016 +32%
TCIM
23
TIAA CREF Investment Management
New York
$2.08M +$308K +12,506 +16%
PAMU
24
Pictet Asset Management (UK)
United Kingdom
$1.98M -$397K -16,100 -16%
EAM
25
Eventide Asset Management
Massachusetts
$1.92M

OMED Hedge Fund Activity: Q2 2015 in Review

83 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2015, worth a combined $235M — down 8.4% from $257M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new OMED positions and 8 closed out — a net gain of 5 holders — while 44 added to existing stakes and 14 trimmed.

The largest buyer was Cannell & Co, adding an estimated $3.36M. The largest seller was Sectoral Asset Management, cutting an estimated $4.05M.

  • 83 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2015, up from 78 in Q1 2015.
  • Funds reported $235M of OncoMed Pharmaceuticals, Inc. stock for Q2 2015, down 8.4% quarter-over-quarter.
  • 13 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2015 and 8 closed out, a net change of +5 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2015 was Cannell & Co, an estimated $3.36M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2015 was Sectoral Asset Management, an estimated $4.05M sold.

Based on aggregated 13F filings for Q2 2015.